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http://dx.doi.org/10.1016/j.ccr.2013.03.033SUMMARYATP competitive inhibitors of the BRAFV600E oncogene paradoxically activate downstream signaling in cells
bearing wild-type BRAF (BRAFWT). In this study, we investigate the biochemical mechanism of wild-type RAF
(RAFWT) activation by multiple catalytic inhibitors using kinetic analysis of purified BRAFV600E and RAFWT
enzymes. We show that activation of RAFWT is ATP dependent and directly linked to RAF kinase activity.
These data support a mechanism involving inhibitory autophosphorylation of RAF’s phosphate-binding
loop that, when disrupted either through pharmacologic or genetic alterations, results in activation of RAF
and the mitogen-activated protein kinase (MAPK) pathway. This mechanism accounts not only for com-
pound-mediated activation of the MAPK pathway in BRAFWT cells but also offers a biochemical mechanism
for BRAF oncogenesis.INTRODUCTION
Gain-of-function mutations that lead to constitutive activation of
the mitogen-activated protein kinase (MAPK) pathway are
among the most common in human cancers. BRAF is mutated
in 50% of melanomas (Davies et al., 2002), and ATP-competi-
tive small molecule inhibitors regress BRAFV600E melanomas,
but not wild-type RAF (RAFWT) tumors (Flaherty et al., 2010).
Not only are RAFWT cancers refractory, but RAF inhibitors para-
doxically increase phosphorylation of downstream effectors
MEK and ERK and induce proliferation in cells with upstream
RAS mutations, which is thought to occur through an allosteric
mechanism involving RAF dimerization (Carnahan et al., 2010;
Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos
et al., 2010). Potentially through a related mechanism, mutations
in the phosphate-binding loop (P loop) of BRAF have been
characterized, which render BRAF catalytically impaired yet
stimulate phosphorylation of downstream targets (Wan et al.,Significance
Data from clinical trials with RAF inhibitors demonstrate dr
oncogene but not in BRAFWT tumors. Preclinical studies show
ically activate the mitogen-activated protein kinase (MAPK) p
RAF inhibitors. This phenomenon is thought to explain the la
spontaneous cutaneous tumors in patients treated with RA
mechanism of RAF kinases that is modulated by catalytic
work has significant implications for the development and
pathway.
594 Cancer Cell 23, 594–602, May 13, 2013 ª2013 Elsevier Inc.2004). However, the underlying biochemistry causing these
phenomena has yet to be fully understood.
RESULTS
To explore the mechanism of paradoxical activation in RAFWT
cells, a panel of selective tool compounds (Cmpds A–G) with a
wide range of potencies against BRAFV600E (Figure 1A; Fig-
ure S1A available online) was tested for activity in both A375
(BRAFV600E mutated) and SW620 (BRAFWT) cell lines. As ex-
pected, all compounds inhibited phosphorylation of the down-
stream MAPK pathway target (pERK) and proliferation in A375
cells (Figure 1B). However, in SW620 cells, each compound acti-
vated ERK in a biphasic pattern with maximal pathway activation
occurring at low compound concentrations andmodest pathway
inhibition at the highest concentrations. This correlated closely
with cell proliferation (also shown previously by others; Carnahan
et al., 2010; Hatzivassiliou et al., 2010; Poulikakos et al., 2010).amatic regression of melanomas carrying the BRAFV600E
that BRAFWT cell lines are not only refractory but paradox-
athway and proliferate when treated with ATP-competitive
ck of efficacy in BRAFWT cancers, as well as emergence of
F inhibitors. In this study, we uncover an autoregulatory
RAF inhibitors and bypassed by BRAF oncogenes. This
therapeutic use of RAF inhibitors for targeting the MAPK
Figure 1. Potent Catalytic BRAFV600E Inhibitors Are Potent RAFWT
Activators In Vitro and In Vivo
(A) Biochemical and cellular potencies for compounds.
(B) A375 (BRAFV600E) and SW620 (BRAFWT and KRASG12V) were treated with
increasing compound concentrations (Cmpd). pERK was measured after 3 hr
of treatment, and cell viability wasmeasured after 4 days. All values expressed
as change from DMSO-treated cells.
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correlated well with compound inhibition half-maximal effective
concentration (EC50) values in A375; the most potent BRAF
V600E
inhibitors in A375 (Cmpd A and Cmpd B) activate the MAPK
pathway at the lowest concentrations in SW620. The observa-
tion that catalytic RAF inhibitors block growth of BRAFV600E cells
but stimulate growth in BRAFWTwith the same relative potencies
led to the hypothesis that RAFWT may negatively regulate the
MAPK pathway through a RAF kinase-dependent mechanism.
Compound Activation of BRAFWT and CRAF Is ATP
Dependent
Having identified a correlation between compound potency for
BRAFV600E inhibition and potency of RAFWT activation in cells,
we investigated if such a correlation is recapitulated biochemi-
cally using isolated RAF proteins. A panel of RAF compounds
was screened for their activity against purified BRAFV600E,
BRAFWT, and CRAFWT kinase domains. All compounds blocked
BRAFV600E phosphorylation of MEK (Figure 1C; Figure S1B).
Each compound also inhibited BRAFWT and CRAF enzymes
but only at a subphysiological ATP concentration (1 mM; Figures
1D, 1E, and S1B). It is surprising that adding compound to
BRAFWT and CRAF at physiological ATP concentrations pro-
moted MEK phosphorylation in a biphasic manner, reminiscent
of the cellular phenomenon. Although previous studies demon-
strate that CRAF undergoes rapid inhibition following activation
(Stokoe and McCormick, 1997), the mechanism is unknown.
As shown in Figure 2A, at conditions approaching cellular ATP
concentrations of 1–5 mM (Traut, 1994) the basal activity of
both RAFWT isoforms was greatly diminished, in contrast to
BRAFV600E, which increased activity at 1 mM ATP. These data
suggest that RAF inhibition is ATP dependent. Furthermore,
compound potency for BRAFWT and CRAF stimulation corre-
lated with compound half-maximal inhibitory concentration
(IC50) for BRAF
V600E inhibition, suggesting again that compound
activation of RAFWT may be linked directly to inhibition of RAF
kinase.
BRAFWT and CRAF Are Autoinhibited at Cellular ATP
Concentrations
The activating V600E substitution in BRAF appears to alter the
apparent Km(ATP) [Km(ATP)app] (Hatzivassiliou et al., 2010). Our
observation that basal kinase activities of BRAFWT and CRAF
were diminished at physiological ATP concentrations suggests
additional kinetic differences between BRAFV600E and BRAFWT.
Whereas BRAFV600E reached a maximum velocity with a calcu-
lated Km(ATP)app of 44 mM, initial rates of catalysis for BRAF
WT
and CRAF were dramatically reduced at ATP concentrations
above 40 mM (Figure 2A). The catalytic rates of bothWT enzymes
did not fit a standard hyperbolic model; thus, we were unable to(C–E) Purified RAF kinase domains were incubated with inhibitor. MEK
phosphorylation was measured after adding ATP. Compounds are shown in
order of potency for BRAFV600E (C) inhibition. Averaged IC50 values at 10 mM
ATP for each compound is depicted by a vertical red dotted line. MEK
phosphorylation measured for BRAFWT (D) and CRAF (E) at 1 mM ATP (gray
dotted line) and 1 mM ATP (black line). Peak enzyme activities shaded in blue
to highlight potency for RAF activation.
See also Figure S1.
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Figure 2. RAFWT Autoinhibition Is Rescued by Catalytic Inhibitors
(A) Enzyme velocity (rate of MEK phosphorylation versus ATP concentration) for BRAFV600E, BRAFWT, and CRAFWT kinase domains. Km(ATP)app was calculated for
BRAFV600E using a standard hyperbolic curve fit [Km(ATP)app = 44 mM]. Fitted curves are shown for BRAF
WT and CRAF, excluding values above 40 mM ATP.
(B) Reaction progress curves for BRAF and CRAF kinase domain.
(C) 50 pM BRAFWT or 4 pM CRAF kinase domains were incubated with 1 mM ATP and Cmpd E for 1 hr. Excess ATP was removed over buffer exchange column.
Initial rates of MEK phosphorylation measured at 1 mM ATP, relative to untreated controls. Error bars denote 95% CI.
(D) CRAF kinase domain (20 nM) was incubated with 1 mM ATP and Cmpd E and run on a 10% SDS-Tris-glycine gel and stained with Coomassie blue.
(E) CRAF kinase domain was treated with 1 mM ATP or no ATP buffer control before removing excess ATP by buffer exchange column. Initial enzyme rates were
thenmeasured in the presence of CmpdC and ATP. Preincubation in 1mMATP reduced apparent Kcat bymore than 85%compared to control. Km(ATP)app values
after ATP treatment were consistent with published values for CRAF (Hatzivassiliou et al., 2010).
See also Figure S2.
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WT and CRAF. Although other
kinases such as KSR have been shown to modulate RAF activity
and affect paradoxical activation (Brennan et al., 2011; McKay
et al., 2011), KSR was not observed with the purified RAF prep-
arations. All wild-type RAF constructs tested were inactivated at
high concentrations of ATP, including BRAF kinase domain iso-
lated to a single band (>95% purity; Figure S2A), suggesting a
RAF-autonomous mechanism.
Although the initial enzymatic rate only appeared diminished at
concentrations approaching 100 mM ATP, evidence of the cata-
lytic rate change was observed for both BRAFWT and CRAF even
at 0.5 mM ATP (Figure 2B), suggesting that RAF autophosphory-
lation occurs, albeit slowly, at concentrations below the
observed initial rate change around 40 mMATP. The rate change
occurred faster as ATP increased and was nearly instantaneous
at the highest concentrations of ATP, causing the observed initial
enzymatic rate to appear diminished. These data strongly sug-
gest that BRAFWT and CRAF are negatively regulated by
autophosphorylation.
To determine if RAF catalytic activity is required, BRAFWT and
CRAFwere incubated at 1mMATP to promote inhibition. Excess
ATP was then removed before kinase activity was measured by
adding MEK substrate and a lower ATP concentration allowing
for maximal RAFWT activity. Preincubation with 1 mM ATP re-
sulted in >80% inhibition of either BRAFWT or CRAF, indicating
that inhibition is a stable modification and is not reversed after
removing ATP (Figure 2C). Therefore, inhibition of RAFWT is not
transient but is consistent with a covalent modification such as
phosphorylation. An electrophoretic mobility shift of CRAF was
also observed only after ATP treatment and without compound
(Figure 2D), again consistent with a phosphorylation event.
Finally, to determine whether RAF kinase activity is required for
ATP inhibition, a selective inhibitor (Cmpd E) was added to the
preincubation step and then removed along with excess ATP
(due to the uniquely low compound dissociation half-life
of <10 min). Preincubation with compound blocked RAF inhibi-
tion (Figure 2C) and prevented CRAF mobility shift (Figure 2D).
Therefore, ATP and RAF catalytic activity are required for inhibi-
tion and putative phosphorylation of WT enzymes. Together,
these data strongly support an inhibitory autokinase mechanism
regulating RAFWT activity.
RAF Compounds Relieve Autoinhibition of RAFWT
Since compound-mediated activation and autoinhibition of RAF
are readily observed at cellular concentrations of ATP, we hy-
pothesized that RAF compounds activate RAFWT by relieving
RAF autoinhibition. If correct, RAF inhibitors should reduce rates
of MEK phosphorylation at subphysiological ATP concentrations
but rescue activity at higher ATP concentrations. Indeed, small
amounts of a potent RAF inhibitor decreased the catalytic rate
of CRAF at low ATP concentrations (Figure 2E). However, at
200 mM and 1 mM ATP, the RAF inhibitor partly rescued CRAF
autoinhibition. These data demonstrate that RAF compounds
block MEK phosphorylation under conditions in which CRAF
autoinhibition is not readily observed and suggests that the
apparent activation of CRAF by compound treatment takes
place through partial rescue of CRAF autoinhibition.
If compound activation of RAFWT can be explained through
preventing autophosphorylation, RAF compounds shouldneither reverse autoinhibition nor activate the autoinhibited
form of enzyme. Rather, compound should only reduce the
remaining catalytic activity of the autoinhibited form of RAF. To
test this, rates of MEK phosphorylation were measured under
several ATP and inhibitor concentrations and compound using
both autoinhibited and control CRAF enzymes. Consistent with
our hypothesis, autoinhibited CRAF exhibited reduced catalytic
activity with standard Michaelis Menten kinetics. Autoinhibited
CRAF was not further inhibited by high ATP concentrations but
reached an apparent Vmax, thereby making calculations for
kinetic rate constants possible (Figure 2E). Furthermore,
although pretreatment with ATP did not affect compound
potency (Figure S2B), the compound did not stimulate CRAF
kinase activity at any tested concentration of compound or
ATP but only decreased the enzymatic rate in a manner con-
sistent with ATP-competitive inhibitor kinetics (Figure 2E),
demonstrating that a catalytic RAF inhibitor cannot activate the
autoinhibited form of CRAF.
P-Loop Autophosphorylation
Preliminary mass spectrometry experiments of BRAF and CRAF
proteins incubated in 1 mM ATP revealed two phosphorylated
peptides that reside in the DFG activation loop and the P loop
(Figures S3A–S3F). To confirm specific inhibitory phosphoryla-
tion site(s), alanine substitutions were made for each serine in
each domain, as well as phosphomimetic (aspartic acid or gluta-
mic acid) substitutions and relative kinase activities were
measured. Phosphomimetic substitutions in the activation loop
of BRAF and CRAF showed no inhibition but were slightly acti-
vating with the exception of CRAFS499D (Figure 3A). However,
BRAF P-loop mutations S465D and S467E had reduced kinase
activity, suggesting that phosphorylation of these serines may
be inhibitory. Curiously, BRAFS465D and BRAFS467E caused
only partial inhibition, raising the question of whether phosphor-
ylation at both sites may be required for complete inactivation.
This hypothesis is further supported by the tandem mass spec-
trometry spectra, which showed phosphorylation of both serines
in the P loop (Figures S3A–S3B, S3E, and S3F). Alternatively,
CRAFS359D blocked nearly all activity, yet CRAFS357D had almost
no effect when compared to the alanine mutation at the same
site (Figure 3A), indicating that S359 may be the primary site of
inhibitory phosphorylation. Each alanine-substituted enzyme
was assayed under low and high ATP concentrations as well
(1 mM ATP and 1 mM ATP, respectively). Although both WT en-
zymes and each of the activation-loop mutants were inhibited
at 1 mM ATP, BRAFS465A, BRAFS467A, and CRAFS359A showed
higher catalytic activity at 1mMATP (Figure 3B). Further profiling
showed that both BRAF P-loop mutations largely rescued ATP-
dependent autoinhibition, and the CRAFS359A mutation
completely reversed the effect while CRAFS357A had no effect
(Figure S3G), demonstrating that serine residues in the P loop
of both enzymes are required for RAF autoinhibition.
To test if P-loop phosphorylation is required for compound
activation, alanine mutants and WT controls were tested at
1 mM ATP. As predicted, BRAFS465A and BRAFS467A had higher
catalytic activity than BRAFWT and were inhibited and not acti-
vated by RAF inhibitor (Figure 3C), demonstrating that both
S465 and S467 are required for compound activation of BRAF.
Similar results were observed for CRAFS359A. To confirmCancer Cell 23, 594–602, May 13, 2013 ª2013 Elsevier Inc. 597
Figure 3. RAFWT Is Autoinhibited through P-Loop Phosphorylation
(A) Serine-to-alanine, aspartic acid, or glutamic acid point mutations were introduced into the P loop and activation loop of BRAF and CRAF. Initial rates of MEK
phosphorylation was measured at 10 mM ATP and normalized to WT control. Error bars denote 95% confidence interval (CI).
(B) MEK phosphorylation measured at 1 mM and 1 mM ATP for alanine substitution mutants. Initial enzymatic rates normalized to enzyme activity at 1 mM ATP.
Error bars denote 95% CI.
(C) Purified enzymes were treated with Cmpd A and 1 mM ATP.
(D) Kinase domain CRAF (50 nM) was incubated under the indicated conditions for 1 hr. The resulting protein was run on an SDS gel, and immunoblots for pCRAF
S359 and for total CRAF (anti-(His)6-tag) are shown. Bands were semiquantified by image intensity area under the curve. Error bars denote SEM.
See also Figure S3.
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against the CRAF phospho-S359 peptide and affinity purified.
PurifiedCRAF kinase domainwas treatedwith ATP and immuno-
blotted using the phospho-specific antibody. CRAF S359
phosphorylation increased after treatment with ATP (Fig-
ure 3D) and diminished after l phosphatase treatment. Phos-
phorylation was also prevented by cotreatment with a RAF
inhibitor, again confirming that CRAF S359 is indeed an auto-
phosphorylation site.
CRAFS359 Is Required for CompoundActivation inCells
To confirm P-loop phosphorylation of endogenous CRAF,
SW620 cells (KRASG12V) were treated with a RAF inhibitor and
CRAF was immunoprecipitated from cell lysates. Compound
treatment inhibited CRAF S359 phosphorylation (Figure 4A),
consistent with the hypothesis that CRAF S359 is an endoge-
nous autophosphorylation site. To test the functional role of
P-loop phosphorylation in cells, HEK293 cells expressing
cMyc-epitope-tagged CRAF or CRAFS359A point mutant were
treated with RAF inhibitor. Overexpression of CRAFWT increased
the ability of compound to stimulate pERK above levels in
endogenous, control cells expressing green fluorescent protein
(GFP) (Figure 4B). However, compound activation was not
observed in CRAFS359A-expressing cells, demonstrating that
CRAF S359 phosphorylation is required. Furthermore, basal
pERK was elevated in CRAFS359A-expressing cells compared
to overexpressed CRAFWT, consistent with the hypothesis that
S359 is an inhibitory phosphorylation site.598 Cancer Cell 23, 594–602, May 13, 2013 ª2013 Elsevier Inc.BRAF P-Loop Mutations Disrupt Compound Activation
Although CRAF overexpression is sufficient to mediate com-
pound activation in HEK293 cells, similar experiments with
BRAF did not promote compound activation of pERK (Figure S4).
However, BRAF mutations have previously been identified in
patient tumor samples that cover nearly every residue of the P
loop, including serine 467 (Akslen et al., 2005), and mutations
of the neighboring glycines (464, 466, and 469) are among the
most frequently occurring non-V600E BRAF mutations (Davies
et al., 2002). This suggested to us not only that the P loop is an
important regulatory domain but also that mutations in this
regionmay activate BRAF by relieving or preventing P-loop auto-
phosphorylation. To test if glycinemutations disrupt P-loop auto-
phosphorylation, we cloned and purified BRAF kinase domains
with a G464V or G464E mutation. Both enzymes were highly
active and displayed no signs of ATP-dependent autoinhibition
(Figure 5A). Km(ATP)app values were calculated and were equiva-
lent to the Km(ATP)app for BRAF
V600E. Furthermore, treatment with
compound did not activate either BRAFG464V or BRAFG464E in the
presence of low (1 mM) or high (1 mM) ATP concentration, sug-
gesting again that autoinhibition through P-loop phosphorylation
is required for compound activation in vitro (Figure 5B).
Having shown that BRAFG464V and BRAFG464E disrupt P-loop
autoinhibition and compound activation in vitro, we wanted to
test if this is also true in a cellular system. Because compound
activation also appears to be exaggerated in context of activated
RAS (Carnahanet al., 2010; Hatzivassiliou et al., 2010; Poulikakos
et al., 2010), two cell lineswere identifiedwith co-occurringBRAF
Figure 4. CRAF S359 Phosphorylation Is
Required for Compound Activation in Cells
(A) SW620 cells were treated with Cmpd A. Total
endogenous CRAF was immunoprecipitated and
then immunoblotted for total and pCRAF S359.
(B) HEK293 cells expressing full-length CRAFWT or
CRAFS359A point mutant harboring a Myc epitope
tagor expressingGFPasacontrolwere treatedwith
Cmpd A for 1 hr. Cell lysates were immunoblotted
for pERK, total ERK, total CRAF, and Myc tag.
See also Figure S4.
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hibitor reduced pERK levels, and no activation was observed in
HEY-A8 (KRASG12D/BRAFG464E) and MDA-MB-231 (KRASG13D/
BRAFG464V) cells (Figure 5C), suggesting that P-loop phosphory-
lation of BRAF is critical for compound activation in cells.
Inhibition of P-Loop Phosphorylation Rescues Catalytic
Activity of RAF Monomers
Previous studies have shown that RAF inhibitors promote
BRAF/CRAF coimmunoprecipitation and promote association
with RAS (Hatzivassiliou et al., 2010; Heidorn et al., 2010), and
it is therefore thought that induced dimerization and/or associa-
tion with RAS may contribute to the paradoxical activation.
However, although treatment with Cmpd A promoted coimmu-
noprecipitation of the BRAF/CRAF complex, no paradoxical
activation was observed in HEY-A8 or MDA-MB-231 cells (Fig-
ure 5C), suggesting that any compound-induced dimerization
was insufficient to activate endogenous RAF. Similar experi-
ments were performed with SW620 cells treated with RAF inhib-
itor, which increased pMEK/pERK levels and promoted BRAF/
CRAF and RAF/RAS coimmunoprecipitation as expected (Fig-
ure 6A). However, these phenomena were frequently not corre-
lated. Figure 6A shows that .01–.1 mM of inhibitor was sufficient
to strongly elevate pMEK and pERK, yet little or no BRAF/CRAF
coimmunoprecipitation was observed until relatively high inhibi-Figure 5. P-Loop Glycine Mutations Prevent Autoinhibition and Consti
(A) Km(ATP)app was calculated for purified BRAF
G464V [Km(ATP)app = 38 mM] and B
(B) Cmpd A IC50 values were calculated for BRAF
G464V and BRAFG464E at 1 mM a
BRAFG464E = 0.3 nM).
(C) KRAS mutant cells with co-occurring BRAF P-loop mutations (HEY-A8 and M
BRAF with CRAF is shown (IP:CRAF) together with pERK immunoblots from whotor concentrations were used (between 0.3 and 3 mM). Similar
observations were made for RAS/RAF coimmunoprecipitation,
suggesting thatmost cellular RAF is cytoplasmic andmonomeric
at inhibitor concentrations that cause very strong pathway acti-
vation. This observation suggests either that very low amounts
of induced dimerization and RAS association is sufficient for
pathway activation or that another mechanism contributes to
paradoxical activation in cells.
To test the relationship between dimerization and catalytic ac-
tivity, point mutations of the putative RAF dimer interface (Pouli-
kakos et al., 2010; Rajakulendran et al., 2009), which disrupt
dimerization, were introduced into the kinase domains of BRAF
and CRAF (CRAFR401A and BRAFR509A). Consistent with results
published by others (Ro¨ring et al., 2012; Baljuls et al., 2011), argi-
nine-to-alanine substitution ablated the kinase activity of the pu-
rified enzyme (Figure 6B), suggesting that monomeric BRAF and
CRAF are inactive. However, BRAFV600E/R509A had similar activity
to BRAFV600E, demonstrating that monomeric BRAFV600E is
active. Since BRAFV600E also does not respond to inhibitory
P-loop autophosphorylation, we hypothesized that disrupting
P-loop phosphorylation, even of RAF monomers, may be suffi-
cient to strongly activate the pathway. Although CRAFR401A
was inactive at all concentrations of ATP tested, mutating the
P-loop autophosphorylation site rendered CRAF unresponsive
to ATP-dependent autoinhibition and strongly rescued kinasetutively Activate BRAF
RAFG464E [Km(ATP)app = 33 mM] kinase domains.
nd 1 mM ATP (Cmpd A IC50 calculated at 1 mM ATP, BRAF
G464V = .07 nM, and
DA-MB-231) were treated with Cmpd A. Increased coimmunoprecipitation of
le cell lysate (WCL).
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Figure 6. Loss of P-Loop Phosphorylation Rescues Catalytic Activity of RAF Monomers
(A) SW620 cells were treated with Cmpd E for 1 hr. Immunoblots of pMEK, pERK from whole cell lysates (WCL), and immunoblots of BRAF/CRAF from
immunoprecipitatated (IP) proteins are shown.
(B) Relative kinase activity of dimer-impaired CRAF (R401A), BRAF (R509A), and BRAFV600E (R509A) (pMEK relative fluorescent units % of control). Error bars
denote SEM.
(C) Catalytic rates of MEK phosphorylation weremeasured for CRAF constructs at 4 mMand 1mMATP. CRAF S359A restores catalytic activity of dimer-impaired
CRAF (CRAFR401A/S359A). Error bars denote SEM.
Cancer Cell
Inhibitory Autophosphorylation of RAF Kinaseactivity of the R401A mutant (Figure 6C), suggesting that
preventing autoinhibition through blocking P-loop autophos-
phorylation is sufficient to strongly activate CRAF monomers.
DISCUSSION
These findings demonstrate that P-loop autophosphorylation is
a critical mechanism regulating RAF kinase activity. Although
P-loop autophosphorylation has not been described previously,
P-loop phosphorylation is known to inhibit several other kinases.
Tyr 15 phosphorylation of CDK1 (Gould and Nurse, 1989; Morla
et al., 1989) and CDK2 (Welburn et al., 2007) inhibits kinase ac-
tivity through steric blockade of ATP and/or peptide substrate
binding. A similar phenomenon has been observed for BCR-
ABL P-loop phosphorylation, though the structural mechanism
of inhibition is unknown but likely differs from CDK regulation
(Skaggs et al., 2006). In the case of BRAF and CRAF, P-loop
phosphorylation did not alter the Km(ATP)app (Figures 2E and
S3G), suggesting that ATP binding is unaffected though blocked
peptide substrate binding, as in the case of CDK2, is a
possibility.
P-loop phosphorylation may also have consequences for acti-
vation-loop conformation. The BRAF crystal structure shows an
interaction between the P loop and the DFG activation loop
through F468 and V600 (Wan et al., 2004). Phosphorylation of
T599 and S602 (or the V600E mutation) is thought to destabilize
this interaction, allowing a shift to the ‘‘DFG-in’’ conformation,
which is required for kinase activity (Chong et al., 2001; Kolch
et al., 1993). Phosphorylation of the P loop at BRAF S465/S467600 Cancer Cell 23, 594–602, May 13, 2013 ª2013 Elsevier Inc.(CRAF S359) may then affect the activation-loop/P-loop interac-
tion, thereby stabilizing the inactive, DFG-out confirmation. Simi-
larly, since BRAFV600E, BRAFG464E, and BRAFG464V were neither
activated by RAF inhibitor nor sensitive to autoinhibition, this
suggests that the mechanism of oncogene activation may be
not only to mimic T599/S601 phosphorylation but also to render
the enzyme unresponsive to P-loop autophosphorylation.
We propose that RAFWT exists in an autoinhibited state at
physiological conditions through autophosphorylation of the P
loop and a competing reaction such as a phosphatase must
be required to frequently renew the pool of active RAF within
the cell. Therefore, catalytic inhibition of RAF would shift the
equilibrium to stabilize the active form by relieving RAF autoinhi-
bition. The inhibitor potency shift observed in RAFWT cells could
therefore be explained by the very high concentrations of RAF
compound required to occupy both RAF molecules and inhibit
MAPK signaling in RAFWT cells.
This model offers a complete explanation for the activation of
RAF kinase by catalytic inhibitors. However, some aspects are
consistent with previous models. Heidorn et al. initially reported
that expression of catalytically inactive BRAF phenocopies RAF
compound treatment and can promote tumor progression in
KRAS-mutated cells. They state that only BRAF-isoform-selec-
tive inhibitors activate the pathway and invoke a mechanism
involving BRAF-mediated regulation of CRAF (Heidorn et al.,
2010). Although MAPK activity in KRAS-mutated cells appears
to be mediated by CRAF (Hatzivassiliou et al., 2010; Poulikakos
et al., 2010), we show that pan RAF inhibitors with high potency
for CRAF inhibition strongly promote MEK phosphorylation
Cancer Cell
Inhibitory Autophosphorylation of RAF Kinasein vitro and in cells (Figures 1 and S1B). Poulikakos et al. showed
that RAF dimer formation is required for compound activation
and hypothesized that binding of compound to one RAF
molecule within a RAF dimer transactivates the adjacent RAF
protomer through a kinase-independent mechanism. If transac-
tivation in cells is entirely allosteric, it must then persist after in-
hibitor dissociation, as no inhibitor is present during cell washes,
lysis, immunoprecipitation, and subsequent kinase assay. An
alternative explanation, which our data support, is that activa-
tion involves a covalent modification. While these mechanisms
are not mutually exclusive, inhibitor treatment did not activate
autoinhibited RAF kinase in vitro (Figure 2E), compound-
induced dimerization alone was not sufficient to activate the
pathway in cells (Figure 5C), and disrupting P-loop phosphory-
lation was sufficient to activate RAF monomers (Figure 6C).
Whereas RAS activity and dimerization likely play a role, these
results suggest that inhibitory P-loop autophosphorylation is
dominant to conformational effects of RAF dimers binding
compound.
Inhibition of P-loop phosphorylation may also have adverse
clinical consequences. Three different clinical RAF inhibitors,
Vemurafenib, XL281, and Sorafenib, promoted dermal squa-
mous cell carcinoma (SCC) and keratoacanthomas (Flaherty
et al., 2010; Schwartz et al., 2009; Dubauskas et al., 2009), which
are likely caused by RAF compound activation of the MAPK
pathway in BRAFWT skin (Carnahan et al., 2010; Hatzivassiliou
et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2010).
Although SCC is not currently a dose-limiting toxicity for mela-
noma patients, efficacy is primarily limited due to acquired resis-
tance to RAF drugs. The median progression free survival for
melanoma patients taking Vemurafenib is limited to 8 months
(Flaherty et al., 2010). In-vitro-acquired resistance modeling
shows that BRAFV600E mutant melanoma cells become depen-
dent on drug for sustained pERK and cell growth (Tap et al.,
2010) through activation of upstream signaling or increased
RAFWT expression (Villanueva et al., 2010; Nazarian et al.,
2010). Furthermore, a recent report indicates that RAF inhibitors
may promote secondary melanomas (Zimmer et al., 2012). RAF
inhibitors themselves may, in fact, be promoting tumor growth
by relieving RAF autoinhibition.EXPERIMENTAL PROCEDURES
Biochemical Kinase Assays
RAF enzyme and MEK substrate proteins were isolated from baculoviral
expression in Sf9 cells via (His)6 tag and Ni-affinity chromatography. Activity
for BRAF and CRAF semipurified protein was determined by AlphaScreen
(PerkinElmer) as described elsewhere (Tsai et al., 2008). Enzyme concentra-
tions used were as follows: BRAF (kinase domain), 50 pM; BRAFV600E (kinase
domain), 100 pM; CRAF (kinase domain), 4 pM; MEK1 (kinase dead), 20 nM,
unless otherwise stated. Compounds were diluted in dimethyl sulfoxide
(DMSO) (2.5% final concentration). Zebda Spin Desalting Columns (Pierce)
were used to remove excess ATP and compound.
Cell Culture and Compounds
All compounds were provided by Novartis Global Discovery Chemistry or the
Genomics Institute of the Novartis Research Foundation and were dissolved in
DMSO (0.2% final concentration). Cell proliferation was measured using Cell
Titer-Glo (Promega). pERK levels were measured by sandwich immunoassay
(Meso Scale Discovery). The following primary antibodies were used for immu-
noblots: ARAF, BRAF, and KRAS (all from Santa Cruz Biotechnology);CRAF (BD Transduction Laboratories); pCRAF S359 (Covance); MEK1/2,
pMEK1/2Ser217/221, ERK1/2, pERK1/2Thr202/Tyr204, and Myc Tag (all from Cell
Signaling Technology); (His)6 (QIAGEN); and for immunoprecipitations, BRAF
(BD Transduction Laboratories), CRAF (Abcam), and RAS (Millipore).
Expression Constructs
pBlueBac4.5 (Invitrogen) vectors were used for baculoviral expression.
BRAFWT and BRAFV600E catalytic domains (residues 437–765) each contain
a C-terminal (His)6 tag, and CRAF catalytic domain (residues 325–648) con-
tains an N-terminal (His)6 tag and two activating point mutations (Y340E and
Y341E, whichmimic SRC phosphorylation and are required for active enzyme;
Fabian et al., 1993). pcDNA3.1/myc-His (Invitrogen) was used for expression
of full-length BRAFWT, CRAFWT, and CRAFS359A constructs in mammalian
cells. Point mutations were introduced using a site-directed mutagenesis kit
(Stratagene).SUPPLEMENTAL INFORMATION
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